Cardiotoxicity Services

Cardiotoxicity is a growing issue in Oncology: cardio-oncology is an emerging discipline focused predominantly on the detection and management of cancer treatment-induced cardiac dysfunction (cardiotoxicity). Around 20% of all cancer survivors will develop cardiovascular co-morbidities, with 1 in 10 cancer patients dying from cardiovascular complication, rather than cancer. In 2016, the European Society of Cardiology (ESC) established a task force of KOLs, raising the urgent need to evaluate the impact of anticancer drugs on cardiotoxicity linked morbidity and mortality. This led to the 2016 ESC position paper  developed under auspices of the ESC committee for Practice Guidelines in the European Heart Journal, Zamorano et al. (2016).